Picetti, Edoardo
Rossi, Sandra
Abu-Zidan, Fikri M.
Ansaloni, Luca
Armonda, Rocco
Baiocchi, Gian Luca
Bala, Miklosh
Balogh, Zsolt J.
Berardino, Maurizio
Biffl, Walter L.
Bouzat, Pierre
Buki, Andras
Ceresoli, Marco
Chesnut, Randall M.
Chiara, Osvaldo
Citerio, Giuseppe
Coccolini, Federico
Coimbra, Raul
Di Saverio, Salomone
Fraga, Gustavo P.
Gupta, Deepak
Helbok, Raimund
Hutchinson, Peter J.
Kirkpatrick, Andrew W.
Kinoshita, Takahiro
Kluger, Yoram
Leppaniemi, Ari
Maas, Andrew I. R.
Maier, Ronald V.
Minardi, Francesco
Moore, Ernest E.
Myburgh, John A.
Okonkwo, David O.
Otomo, Yasuhiro
Rizoli, Sandro
Rubiano, Andres M.
Sahuquillo, Juan
Sartelli, Massimo
Scalea, Thomas M.
Servadei, Franco
Stahel, Philip F.
Stocchetti, Nino
Taccone, Fabio S.
Tonetti, Tommaso
Velmahos, George
Weber, Dieter
Catena, Fausto
Article History
Received: 3 September 2019
Accepted: 4 October 2019
First Online: 29 November 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: AWK has consulted for the Innovative Trauma Care and Acelity Corporations. PFS is the co-inventor of the US patent no. 11.441.828 entitled: “Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury, and related conditions.” All other authors declare that they have no competing interests.